Michael is a serial entrepreneur with over 20 years experience building and leading high-growth organizations. He was successfully treated for Stage IV throat cancer in 2008.
Prior to CancerAI, Michael was CEO of FeatureX, an AI startup focused on deep learning computer vision technology.
Michael started his career as an officer aboard the USS La Jolla (SSN-701), a nuclear-powered fast attack submarine. He is an inventor (US Patent 8732065) and has degrees from Notre Dame, MIT, and The Fletcher School at Tufts University.
Bob is a Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology. The Weinberg lab is known for its discoveries of the first human oncogene – the Ras oncogene that causes normal cells to form tumors, and the isolation of the first known tumor suppressor gene - the Rb gene.
His lab now primarily focuses on two areas: the interactions between epithelial and mesenchymal cells that produce carcinomas and the processes by which cancer cells invade and metastasize.
Bob is a Member of the U.S. National Academy of Sciences, and his many awards include the National Medal of Science (1997), Wolf Prize in Medicine (2004), Landon-AACR Prize for Cancer Research (2006), Otto Warburg Medal (2007), Breakthrough Prize in Life Sciences (2013), and the Salk Medal (2016).
MACHINE LEARNING ADVISOR
Regina is a professor in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory (CSAIL) at the Massachusetts Institute of Technology. Her research interests are in natural language processing and applications of deep learning to chemistry and oncology.
In 2017, she received a MacArthur "genius grant" fellowship, an ACL fellowship and an AAAI fellowship. She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL. She received her Ph.D. in Computer Science from Columbia University, and spent a year as a postdoc at Cornell University.
Jack Szostak is biologist, Professor of Genetics at Harvard Medical School, and Alexander Rich Distinguished Investigator at Massachusetts General Hospital, Boston.
Jack has made significant contributions to the field of genetics. His achievement helped scientists to map the location of genes in mammals and to develop techniques for manipulating genes. His research findings in this area are also instrumental to the Human Genome Project.
He was awarded the 2009 Nobel Prize for Physiology or Medicine, along with Elizabeth Blackburn and Carol W. Greider. Their discovery of how chromosomes are protected by telomeres may improve our understanding of cancer cell "immortality."
Daniel Haber is the Director of the Cancer Center at Massachusetts General Hospital.
Daniel’s research has focused primarily in the field of cancer genetics, resulting in discoveries on the origin of the pediatric kidney cancer Wilms tumor, genetic predispositions to breast cancer, and mutations that define a subset of “non-smoker” lung cancers that are uniquely sensitive to targeted new therapies.
The Haber lab has developed a novel technology for isolating rare circulating tumor cells (CTCs) from the blood of cancer patients—a tool that may have profound implications for early diagnosis of cancer and for non-invasive molecular profiling of cancers during therapy.
Dr. Haber was appointed to the Howard Hughes Medical Institute in 2008, and he was elected to the Institute of Medicine in 2009, the American Academy of Arts and Sciences in 2011, and the National Academy of Sciences in 2018.